m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05686
 [1]
m6A modification Circ_MYO1C Circ_MYO1C METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA circMYO1C CD274  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Circ_MYO1C
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_MYO1C circRNA View Details
Regulated Target CD274 molecule (CD274) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary Mechanistically, Circ_MYO1C cyclization was mediated by m6A methyltransferase METTL3. Moreover, methylated RNA immunoprecipitation sequencing (MeRIP-seq) unveiled the remarkable m6A modification on CD274 molecule (CD274) mRNA. Moreover, circMYO1C targeted the m6A site of PD-L1 mRNA to enhance its stability by cooperating with IGF2BP2, thereby accelerating PDAC immune escape.
Responsed Disease Pancreatic ductal adenocarcinoma ICD-11: 2C10.0
 Disease Info 
Cell Process Cell proliferation
Cell migration
In-vitro Model
 PANC-1 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
Capan-2 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0026
BxPC-3 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0186
CFPAC-1 Cystic fibrosis Homo sapiens CVCL_1119
In-vivo Model Male BALB/c nude mice (5-6 weeks) were obtained from Slac Laboratory Animal Center (Shanghai, China) and maintained under pathogen-free conditions. PANC-1 cells (2 × 106 cells suspended in 100 μl PBS) transfected with circMYO1C knockdown (sh-circMYO1C) or controls (sh-NC) were subcutaneously injected into the flank of nude mice. One week later, the tumor size was measured every three days.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
CD274 molecule (CD274) 55 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Avelumab Approved [2]
External Link
TTD: D0K7SX
 Compound Name Durvalumab Approved [3]
MOA Modulator
External Link
TTD: D0LS9E
 Compound Name RG-7446 Approved [4]
External Link
TTD: D0OZ4J
 Compound Name Bavencio Approved [5]
MOA Inhibitor
External Link
TTD: D0W8HN
 Compound Name Atezolizumab Approved [6]
External Link
TTD: D0YM2K
 Compound Name Sugemalimab Approved in China [7]
External Link
TTD: DDZ48Y
 Compound Name MEDI4736 Phase 3 [8]
MOA Modulator
External Link
TTD: D04RRZ
 Compound Name MPDL-3280A Phase 3 [9]
MOA Modulator
External Link
TTD: D0Y5IH
 Compound Name CS1001 Phase 3 [10]
External Link
TTD: D3MP1S
 Compound Name A167 Phase 3 [11]
Synonyms
KL-A167
    Click to Show/Hide
External Link
TTD: DI89WD
 Compound Name KN046 Phase 3 [12]
MOA Inhibitor
External Link
TTD: DLOQ25
 Compound Name Pidilizumab Phase 2 [13]
Synonyms
CT-011
    Click to Show/Hide
External Link
TTD: D09MRL
 Compound Name KN035 Phase 2 [14]
Synonyms
Envafolimab
    Click to Show/Hide
External Link
TTD: D0GF2R
 Compound Name CX-072 Phase 2 [15]
MOA Inhibitor
External Link
TTD: D0Z2BO
 Compound Name INCB86550 Phase 2 [16]
MOA Inhibitor
External Link
TTD: DKM79E
 Compound Name Bintrafusp alfa Phase 2 [17]
External Link
TTD: D5J3BL
 Compound Name M7824 Phase 2 [18]
MOA Inhibitor
External Link
TTD: D05FPZ
 Compound Name BGB-A333 Phase 1/2 [19]
External Link
TTD: DC5VW9
 Compound Name GS-4224 Phase 1/2 [20]
Synonyms
Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 12439252
TTD: DS6VD0
 Compound Name NM21-1480 Phase 1/2 [21]
MOA Modulator
External Link
TTD: DUVH60
 Compound Name LY3300054 Phase 1 [18]
External Link
TTD: D08HSS
 Compound Name MSB2311 Phase 1 [14]
External Link
TTD: D0A8AU
 Compound Name Anti-PD-L1 Phase 1 [22]
Synonyms
BMS-936559
    Click to Show/Hide
External Link
TTD: D0KP9A
 Compound Name FAZ053 Phase 1 [15]
MOA Inhibitor
External Link
TTD: D0LU1O
 Compound Name Anti-PD-L1 CSR T cells Phase 1 [23]
MOA CAR-T-Cell-Therapy
External Link
TTD: D0W7UD
 Compound Name BMS-986189 Phase 1 [14]
MOA Inhibitor
External Link
TTD: D0X1GN
 Compound Name Cosibelimab Phase 1 [24]
Synonyms
CK-301/TG-1501
    Click to Show/Hide
External Link
TTD: D17URP
 Compound Name CA-170 Phase 1 [25]
MOA Inhibitor
External Link
TTD: D2Z6WF
 Compound Name PD-L1 t-haNK Phase 1 [26]
External Link
TTD: DH42RF
 Compound Name KD033 Phase 1 [27]
MOA Inhibitor
External Link
TTD: DJVR06
 Compound Name C-Met/PD-L1 CAR-T Cell Phase 1 [28]
MOA CAR-T-Cell-Therapy(Dual specific)
External Link
TTD: D03GTO
 Compound Name CA-170 Phase 1 [18]
Synonyms
3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 16212596
TTD: D09PPU
 Compound Name FS118 Phase 1 [14]
External Link
TTD: D0XO9F
 Compound Name PF-07257876 Phase 1 [29]
External Link
TTD: D1A7OP
 Compound Name MCLA-145 Phase 1 [30]
MOA Agonist
External Link
TTD: D2QY0Z
 Compound Name GEN1046 Phase 1 [31]
MOA Agonist
External Link
TTD: D3HBJ1
 Compound Name ALPN-202 Phase 1 [32]
MOA Inhibitor
External Link
TTD: D82UVG
 Compound Name TAK-252 Phase 1 [33]
Synonyms
SL-279252
    Click to Show/Hide
MOA Agonist
External Link
TTD: D9SL1N
 Compound Name INBRX-105 Phase 1 [34]
MOA Inhibitor
External Link
TTD: DA1X5W
 Compound Name LY3415244 Phase 1 [35]
MOA Inhibitor
External Link
TTD: DC8HR6
 Compound Name A337 Phase 1 [11]
External Link
TTD: DL97UQ
 Compound Name IBI318 Phase 1 [36]
MOA Inhibitor
External Link
TTD: DX30BA
 Compound Name PMID30107136-Compound-Example2 Patented [37]
MOA Inhibitor
Activity IC50 = 150 nM
External Link
CID: 117941742
TTD: D0OK1S
 Compound Name PMID30107136-Compound-Example1 Patented [37]
MOA Inhibitor
Activity IC50 = 18 nM
External Link
CID: 117951478
TTD: D0WQ9X
 Compound Name PMID30247903-Compound-General structure7 Investigative [14]
Synonyms
PMID30247903Compound7
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D01TGF
 Compound Name CA-327 Investigative [14]
MOA Inhibitor
External Link
TTD: D04ILU
 Compound Name PMID30247903-Compound-General structure8 Investigative [14]
Synonyms
PMID30247903Compound8
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D04QGF
 Compound Name PMID30247903-Compound-General structure5 Investigative [14]
Synonyms
PMID30247903Compound5
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D07BOF
 Compound Name PMID30247903-Compound-General structure12 Investigative [14]
Synonyms
PMID30247903Compound12
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D09BYN
 Compound Name PMID30247903-Compound-General structure9 Investigative [14]
Synonyms
PMID30247903Compound9
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0GG6N
 Compound Name PMID30247903-Compound-General structure6 Investigative [14]
Synonyms
PMID30247903Compound6
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0TN4F
 Compound Name PMID30247903-Compound-General structure10 Investigative [14]
Synonyms
PMID30247903Compound10
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0XL3N
 Compound Name YH011 Investigative [38]
External Link
TTD: DA91UG
 Compound Name YH010 Investigative [39]
External Link
TTD: DBTI39
 Compound Name RG6084 Phase 1 [40]
External Link
TTD: DJX7K9
2C10: Pancreatic cancer 182 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Atezolizumab Approved [18]
External Link
TTD: D0YM2K
 Compound Name Trimethadione Approved [41]
Synonyms
Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]
    Click to Show/Hide
External Link
CID: 5576
TTD: D0U4VT
DrugBank: DB00347
 Compound Name Motixafortide Approved [18]
External Link
CID: 91865076
TTD: D0T6CN
DrugBank: DB14939
 Compound Name Uridine triacetate Approved [42]
Synonyms
PN401
    Click to Show/Hide
External Link
CID: 20058
TTD: D0OL7F
DrugBank: DB09144
 Compound Name Bentiromide Approved [43]
Synonyms
Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so
    Click to Show/Hide
External Link
CID: 6957673
TTD: D0L0SW
DrugBank: DB00522
 Compound Name Olaparib Approved [18]
Synonyms
AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
    Click to Show/Hide
External Link
CID: 23725625
TTD: D0J9HW
DrugBank: DB09074
 Compound Name Streptozocin Approved [44]
Synonyms
Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose
    Click to Show/Hide
External Link
CID: 29327
TTD: D0I8RR
DrugBank: DB00428
 Compound Name Plazomicin Phase 3 [45]
Synonyms
ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,
    Click to Show/Hide
External Link
CID: 42613186
TTD: D0E6BB
DrugBank: DB12615
 Compound Name Taxol Approved [18]
Synonyms
C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
    Click to Show/Hide
External Link
CID: 36314
TTD: D0C4RB
DrugBank: DB01229
 Compound Name Ibrutinib Phase 3 [18]
Synonyms
PCI-32765; Ibrutinib (BTK inhibitor)
    Click to Show/Hide
External Link
CID: 24821094
TTD: D09KTS
DrugBank: DB09053
 Compound Name Erlotinib Approved [46]
Synonyms
Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
    Click to Show/Hide
External Link
CID: 176870
TTD: D07POC
DrugBank: DB00530
 Compound Name Ruxolitinib Approved [47]
Synonyms
Ruxolitinib (JAK inhibitor)
    Click to Show/Hide
External Link
CID: 25126798
TTD: D04LKS
DrugBank: DB08877
 Compound Name Nivolumab Approved [18]
External Link
TTD: D00GOV
 Compound Name Coenzyme Q10 Phase 2 [18]
Synonyms
CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen
    Click to Show/Hide
External Link
CID: 5281915
TTD: D01ZUA
DrugBank: DB09270
 Compound Name Aglatimagene besadenovec Phase 1/2 [18]
External Link
TTD: DE8H1W
 Compound Name Zolbetuximab Phase 3 [48]
Synonyms
IMAB362
    Click to Show/Hide
External Link
TTD: D4HQ1F
 Compound Name AC-1204 Phase 3 [49]
Synonyms
isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA
    Click to Show/Hide
External Link
CID: 12311031
TTD: D0Y1RN
 Compound Name Radiosensitizer gene therapy Phase 3 [50]
Synonyms
Radiosensitizer gene therapy (prostate cancer)
    Click to Show/Hide
External Link
TTD: D0X4NF
 Compound Name Glufosfomide Phase 3 [51]
External Link
TTD: D0W7PQ
 Compound Name Yttrium (90Y) clivatuzumab tetraxetan Phase 3 [52]
Synonyms
PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4
    Click to Show/Hide
External Link
TTD: D0V2KR
 Compound Name Y-90 Clivatuzumab Phase 3 [53]
External Link
TTD: D0T8AI
 Compound Name Civacir Phase 3 [54]
External Link
TTD: D0P9UP
 Compound Name GV1001 Phase 3 [55]
External Link
TTD: D0N0QC
 Compound Name Masitinib Phase 3 [18]
Synonyms
790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
    Click to Show/Hide
External Link
CID: 10074640
TTD: D0MW0N
DrugBank: DB11526
 Compound Name Glufosfamide Phase 3 [18]
Synonyms
Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol
    Click to Show/Hide
External Link
CID: 123628
TTD: D0L9IA
DrugBank: DB06177
 Compound Name Sapacitabine Phase 3 [18]
Synonyms
CYC682
    Click to Show/Hide
External Link
CID: 153970
TTD: D0D4RF
DrugBank: DB06365
 Compound Name Pelareorep Phase 2 [15]
External Link
TTD: D0BF8Y
 Compound Name Pamrevlumab Phase 3 [56]
External Link
TTD: D09TJJ
 Compound Name GRASPA Phase 1 [57]
Synonyms
L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech
    Click to Show/Hide
External Link
TTD: D09JKS
 Compound Name Pancreas algenpantucel-L Phase 3 [58]
Synonyms
HyperAcute (TN)
    Click to Show/Hide
External Link
TTD: D08PBQ
 Compound Name CPI-613 Phase 3 [59]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
CID: 24770514
TTD: D07NVI
DrugBank: DB12109
 Compound Name Zarnestra Phase 3 [60]
Synonyms
JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE
    Click to Show/Hide
External Link
CID: 159324
TTD: D07NPS
DrugBank: DB04960
 Compound Name MM-398 Phase 3 [61]
External Link
CID: 91809656
TTD: D07HOH
 Compound Name Marimastat Phase 3 [62]
Synonyms
Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide
    Click to Show/Hide
External Link
CID: 119031
TTD: D05VZE
DrugBank: DB00786
 Compound Name AM0010 Phase 3 [63]
External Link
TTD: D03MYX
 Compound Name ANX-510 Phase 3 [64]
External Link
CID: 135400185
TTD: D01YKI
 Compound Name Napabucasin Phase 3 [18]
Synonyms
83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919
    Click to Show/Hide
External Link
CID: 10331844
TTD: D01IGZ
DrugBank: DB12155
 Compound Name Algenpantucel-L Phase 3 [65]
Synonyms
HyperAcute pancreas (TN)
    Click to Show/Hide
External Link
TTD: D00HSK
 Compound Name OT-101 Phase 2/3 [18]
External Link
TTD: DO5H6K
 Compound Name RP101 Phase 2/3 [66]
Synonyms
SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,
    Click to Show/Hide
External Link
CID: 446727
TTD: D0Z9LP
DrugBank: DB03312
 Compound Name NLG8189 Phase 2/3 [18]
Synonyms
1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189
    Click to Show/Hide
External Link
CID: 405012
TTD: D0B5HS
DrugBank: DB12827
 Compound Name LY2157299 Phase 2/3 [18]
Synonyms
Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
    Click to Show/Hide
External Link
CID: 10090485
TTD: D06TFI
DrugBank: DB11911
 Compound Name SM-88 Phase 2/3 [67]
External Link
CID: 3125
TTD: D03ZDX
 Compound Name SiG12D-LODER Phase 2 [18]
External Link
TTD: DNH67V
 Compound Name BNT141 Phase 2 [68]
External Link
TTD: DFZ19J
 Compound Name BNT321 Phase 2 [69]
Synonyms
MVT-5873
    Click to Show/Hide
External Link
TTD: D7AOL8
 Compound Name BPM 31510 Phase 2 [70]
External Link
TTD: D4MZR2
 Compound Name GC4711 Phase 2 [71]
Synonyms
UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,
    Click to Show/Hide
External Link
CID: 131634674
TTD: D3P8JK
 Compound Name CYTO-401 Phase 2 [72]
External Link
TTD: D2Q5XO
 Compound Name Zenocutuzumab Phase 2 [73]
External Link
TTD: D1J4CI
 Compound Name Cabiralizumab Phase 2 [18]
External Link
TTD: D0YO4B
 Compound Name VS-6063 Phase 2 [18]
Synonyms
Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu
    Click to Show/Hide
External Link
CID: 25117126
TTD: D0Y1UO
DrugBank: DB12282
 Compound Name MENK Phase 2 [51]
External Link
TTD: D0VG7I
 Compound Name CO-101 Phase 2 [74]
Synonyms
methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester
    Click to Show/Hide
External Link
CID: 9828310
TTD: D0V0CJ
DrugBank: DB12564
 Compound Name MENK Phase 2 [18]
Synonyms
IRT-101
    Click to Show/Hide
External Link
TTD: D0TN1J
 Compound Name TL-118 Phase 2 [75]
Synonyms
Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma
    Click to Show/Hide
External Link
TTD: D0T9OC
 Compound Name Antroquinonol Phase 2 [18]
Synonyms
Hocena; Fungal extract (cancer), Golden Biotechnology
    Click to Show/Hide
External Link
CID: 24875259
TTD: D0T3AW
DrugBank: DB12326
 Compound Name NPC-1C Phase 2 [18]
Synonyms
Ensituximab
    Click to Show/Hide
External Link
TTD: D0T2FC
 Compound Name Necuparanib Phase 2 [76]
External Link
TTD: D0S3CX
 Compound Name CCX872 Phase 2 [18]
External Link
TTD: D0Q3PB
 Compound Name GC4419 Phase 1/2 [18]
Synonyms
Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-
    Click to Show/Hide
External Link
CID: 71587734
TTD: D0PV9N
 Compound Name Istiratumab Phase 2 [15]
External Link
TTD: D0P4ZR
 Compound Name GI-4000 Phase 2 [77]
External Link
TTD: D0N4SF
 Compound Name OCV-101 Phase 2 [78]
Synonyms
OTS-11101
    Click to Show/Hide
External Link
TTD: D0LX8Z
 Compound Name RX-3117 Phase 2 [18]
Synonyms
Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva
    Click to Show/Hide
External Link
CID: 11242315
TTD: D0L7WS
 Compound Name Ensitiximab Phase 2 [51]
External Link
TTD: D0KL4T
 Compound Name GI-4000 + gemcitabine Phase 2 [79]
External Link
TTD: D0KK9V
 Compound Name BC-819 Phase 2 [80]
External Link
TTD: D0K0KQ
 Compound Name IRT-102 Phase 2 [81]
External Link
CID: 42785
TTD: D0J5UK
 Compound Name LE-DT Phase 2 [82]
Synonyms
Liposomal docetaxel
    Click to Show/Hide
External Link
TTD: D0J2NX
 Compound Name TH-302 Phase 2 [18]
Synonyms
evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174
    Click to Show/Hide
External Link
CID: 11984561
TTD: D0H1EA
DrugBank: DB06091
 Compound Name Demcizumab Phase 2 [51]
External Link
TTD: D0GJ7N
 Compound Name Anti-PSCA mab Phase 2 [83]
External Link
TTD: D0G7ZT
 Compound Name ALT-803 Phase 2 [15]
Synonyms
IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience
    Click to Show/Hide
External Link
TTD: D0FD7H
 Compound Name ARQ 761 Phase 2 [18]
External Link
TTD: D0DR0P
 Compound Name Reolysinpelareorep Phase 2 [18]
External Link
TTD: D0CW2N
 Compound Name PBI-05204 Phase 2 [18]
External Link
CID: 11541511
TTD: D0A4YK
DrugBank: DB12843
 Compound Name PCI-27483 Phase 2 [84]
External Link
CID: 135425273
TTD: D09TFL
DrugBank: DB13000
 Compound Name RX-0201 Phase 2 [51]
External Link
TTD: D07SYZ
 Compound Name CP-613 Phase 2 [85]
External Link
TTD: D07FXF
 Compound Name CART 19 Preclinical [86]
External Link
TTD: D06TKR
 Compound Name VT-122 Phase 1 [51]
External Link
TTD: D05VKS
 Compound Name PEGPH20 Phase 2 [87]
External Link
TTD: D05INV
 Compound Name Ficlatuzumab Phase 2 [18]
Synonyms
AV-299
    Click to Show/Hide
External Link
TTD: D03UBW
 Compound Name Tigatuzumab Phase 2 [88]
External Link
TTD: D03LTO
 Compound Name CRS-207 Phase 2 [89]
External Link
TTD: D02WSB
 Compound Name CAP1-6D Phase 2 [90]
Synonyms
Modified CEA peptide (pancreatic cancer), University of Chicago
    Click to Show/Hide
External Link
CID: 396060
TTD: D02UKX
 Compound Name SGT-53 Phase 2 [18]
Synonyms
P53 gene stimulator (solid tumor), Synergene Therapeutics
    Click to Show/Hide
External Link
TTD: D02EOH
 Compound Name Tarextumab Phase 2 [91]
External Link
TTD: D01QLP
 Compound Name BVD-523 Phase 2 [18]
External Link
CID: 11719003
TTD: D01IED
DrugBank: DB13930
 Compound Name Ocaperidone Phase 2 [15]
Synonyms
Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019
    Click to Show/Hide
External Link
CID: 71351
TTD: D01FQR
DrugBank: DB06229
 Compound Name Encapsulated live cells converting ifosfamide Phase 2 [18]
External Link
TTD: D01DLT
 Compound Name LY2603618 Phase 2 [92]
Synonyms
Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618 IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea
    Click to Show/Hide
External Link
CID: 11955855
TTD: D00NZL
DrugBank: DB11662
 Compound Name Salirasib Discontinued in Phase 1/2 [93]
Synonyms
162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032
    Click to Show/Hide
External Link
CID: 5469318
TTD: D00KTV
DrugBank: DB12681
 Compound Name MM-141 Phase 2 [18]
External Link
TTD: D00BUO
 Compound Name GB1275 Phase 1/2 [94]
External Link
TTD: DZ5K6F
 Compound Name ABTL0812 Phase 1/2 [95]
Synonyms
(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ
    Click to Show/Hide
External Link
CID: 21158511
TTD: DMBQ10
 Compound Name GP-2250 Phase 1/2 [96]
External Link
TTD: DARV32
 Compound Name Delolimogene mupadenorepvec Phase 1/2 [97]
Synonyms
LOAd703
    Click to Show/Hide
External Link
TTD: D5V7XP
 Compound Name GSK3145095 Phase 1/2 [98]
Synonyms
1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)
    Click to Show/Hide
External Link
CID: 118557502
TTD: D0Z7BX
 Compound Name Encapsulated cell therapy Phase 1/2 [99]
External Link
TTD: D0XY8C
 Compound Name ETBX-011 cancer vaccine Phase 1/2 [77]
External Link
TTD: D0U1WU
 Compound Name BPX-601 Phase 1/2 [100]
External Link
TTD: D0TY6U
 Compound Name NANT Phase 1/2 [18]
External Link
TTD: D0T4GG
 Compound Name BrevaRex Phase 1/2 [101]
Synonyms
BrevaRex MAb; monoclonal antibody
    Click to Show/Hide
External Link
TTD: D0M5JC
 Compound Name DCVax-Pancreas Phase 1/2 [102]
Synonyms
Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics
    Click to Show/Hide
External Link
TTD: D0L7LT
 Compound Name PEGylated hyaluronidase (human recombinant) Phase 1/2 [103]
Synonyms
PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme
    Click to Show/Hide
External Link
TTD: D0L5IA
 Compound Name CAR-T cells targeting mesothelin Phase 1/2 [104]
External Link
TTD: D0KC2S
 Compound Name MALP-2S Phase 1/2 [105]
External Link
TTD: D0K3SM
 Compound Name Anti-Mesothelin CAR-T cells Phase 1/2 [106]
External Link
TTD: D0BE6M
 Compound Name Anti-MUC1 CAR T Cells Phase 1/2 [107]
External Link
TTD: D08WII
 Compound Name Anti-HER2 CAR-T Phase 1/2 [108]
External Link
TTD: D08QZH
 Compound Name CAR-T Cells targeting EpCAM Phase 1/2 [109]
External Link
TTD: D08QYW
 Compound Name Anti-MUC1 AR20.5 Phase 1/2 [15]
External Link
TTD: D07YGQ
 Compound Name AR20.5 Phase 1/2 [18]
External Link
TTD: D07PCZ
 Compound Name G0-203-2c Phase 1/2 [110]
External Link
TTD: D04WHM
 Compound Name LOAd703 Phase 1/2 [18]
External Link
TTD: D03ZIP
 Compound Name Anti-mesothelin CAR transduced PBL Phase 1/2 [111]
External Link
TTD: D00YXG
 Compound Name M9241 Phase 1 [112]
Synonyms
NHS-IL12
    Click to Show/Hide
External Link
TTD: DO8W9E
 Compound Name NBF-006 Phase 1 [113]
External Link
TTD: D8UZ5R
 Compound Name AB680 Phase 1 [114]
Synonyms
AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH
    Click to Show/Hide
External Link
CID: 130205852
TTD: D7CE6N
 Compound Name STAT400 Phase 1 [115]
External Link
TTD: D75WVO
 Compound Name CEND-1 Phase 1 [116]
Synonyms
iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide
    Click to Show/Hide
External Link
CID: 134611625
TTD: D5WU7B
 Compound Name CAR-T Cells targeting EGFRvIII Phase 1 [117]
External Link
TTD: D0ZQ6N
 Compound Name HuCART-meso cells Phase 1 [118]
External Link
TTD: D0ZF9J
 Compound Name OCV-105 Phase 1 [119]
Synonyms
Cancer vaccine (pancreas), Otsuka/OncoTherapy
    Click to Show/Hide
External Link
TTD: D0X9YB
 Compound Name SBP-101 Phase 1 [51]
Synonyms
diethyl dihydroxyhomospermine
    Click to Show/Hide
External Link
TTD: D0VE9F
 Compound Name RG7882 Phase 1 [15]
External Link
TTD: D0V7QW
 Compound Name CART-meso-19 T cells Phase 1 [120]
External Link
TTD: D0V5DD
 Compound Name MOv19-BBz CAR T cells Phase 1 [121]
External Link
TTD: D0T7CR
 Compound Name Anti-MUC1 AR20.5 mab Phase 1 [122]
External Link
TTD: D0S3AE
 Compound Name Anti-CEA-CAR T Phase 1 [123]
External Link
TTD: D0S1QN
 Compound Name MVT-5873 Phase 1 [15]
External Link
TTD: D0Q5QV
 Compound Name CART-meso cells Phase 1 [124]
External Link
TTD: D0P2GA
 Compound Name CAR-20/19-T Cells Phase 1 [125]
External Link
TTD: D0NU9L
 Compound Name CARTmeso/19 Phase 1 [126]
External Link
TTD: D0MD8S
 Compound Name CAR-T Cells targeting Mesothelin Phase 1 [117]
External Link
TTD: D0L7OJ
 Compound Name CAR-T Cells targeting CEA Phase 1 [117]
External Link
TTD: D0L6HU
 Compound Name HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine Phase 1 [127]
Synonyms
HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)
    Click to Show/Hide
External Link
TTD: D0K6UQ
 Compound Name Anti-hCD70 CAR transduced PBL Phase 1 [128]
External Link
TTD: D0JO9M
 Compound Name MORAb-066 Phase 1 [129]
Synonyms
Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek
    Click to Show/Hide
External Link
TTD: D0H8PX
 Compound Name Anti-MUC1 mab Phase 1 [130]
External Link
TTD: D0H2CF
 Compound Name Anti-meso-CAR vector transduced T cells Phase 1 [131]
External Link
TTD: D0G4GY
 Compound Name CRS-207 + GVAX Phase 2 [51]
External Link
TTD: D0EY1Y
 Compound Name Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1 Phase 1 [132]
External Link
TTD: D0EB0Y
 Compound Name Meso-CART Phase 1 [133]
External Link
TTD: D0D2LE
 Compound Name ASG-5ME Phase 1 [134]
External Link
TTD: D0BC6M
 Compound Name Anti-CD133-CAR vector-transduced T cells Phase 1 [135]
External Link
TTD: D09HRH
 Compound Name IRX4204 Phase 1 [18]
Synonyms
220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid
    Click to Show/Hide
External Link
CID: 9863341
TTD: D09DJC
DrugBank: DB11806
 Compound Name AbGn-107 Phase 1 [18]
External Link
TTD: D08GZE
 Compound Name LMB-100 Phase 1/2 [18]
External Link
TTD: D07RDQ
 Compound Name PLX7486 Phase 1 [136]
External Link
TTD: D07PSL
 Compound Name CAR-T Cells targeting HER2 Phase 1 [117]
External Link
TTD: D06XWD
 Compound Name CAR-T Cells targeting MUCI Phase 1 [117]
External Link
TTD: D06URX
 Compound Name SEL-403 Phase 1 [18]
External Link
TTD: D03ZLN
 Compound Name CAR-T Cells targeting PSCA Phase 1 [117]
External Link
TTD: D02MYI
 Compound Name Anti-CEA CAR-T cells Phase 1 [137]
External Link
TTD: D00KDQ
 Compound Name MVT-1075 Phase 1 [18]
External Link
TTD: D00IFQ
 Compound Name CAR-CLD18 T cell Clinical trial [138]
External Link
TTD: D06CWZ
 Compound Name CART-meso cells Clinical trial [139]
External Link
TTD: D04WZL
 Compound Name PMID28460551-Compound-1 Patented [140]
External Link
CID: 25190990
TTD: D0IH3I
DrugBank: DB14866
 Compound Name Tanomastat Discontinued in Phase 3 [141]
Synonyms
Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
    Click to Show/Hide
External Link
CID: 6918336
TTD: D0Q1CD
DrugBank: DB06276
 Compound Name Larotaxel Discontinued in Phase 3 [142]
Synonyms
Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881
    Click to Show/Hide
External Link
CID: 6918260
TTD: D0J0RV
DrugBank: DB12984
 Compound Name Apricoxib Discontinued in Phase 2 [143]
Synonyms
TG01
    Click to Show/Hide
External Link
CID: 9820073
TTD: D0S7IZ
DrugBank: DB12378
 Compound Name Lintitript Discontinued in Phase 2 [144]
Synonyms
SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid
    Click to Show/Hide
External Link
CID: 122077
TTD: D01ZXW
DrugBank: DB04867
 Compound Name Merbarone Discontinued in Phase 2 [145]
Synonyms
NSC-336628
    Click to Show/Hide
External Link
CID: 4990817
TTD: D00VZF
 Compound Name LY293111 Discontinued in Phase 2 [146]
Synonyms
Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny
    Click to Show/Hide
External Link
CID: 177941
TTD: D00GNK
DrugBank: DB12850
 Compound Name HMN-214 Discontinued in Phase 1 [147]
Synonyms
N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide
    Click to Show/Hide
External Link
CID: 9888590
TTD: D0R7ID
 Compound Name RG7600 Discontinued in Phase 1 [148]
External Link
TTD: D04TYP
 Compound Name IC261 Preclinical [149]
Synonyms
IC-261; IC 261
    Click to Show/Hide
External Link
CID: 5288600
TTD: D0UN8H
DrugBank: DB03083
 Compound Name ANAVEX 1007 Preclinical [150]
External Link
TTD: D0M6OW
 Compound Name IPH-4201 Terminated [151]
Synonyms
MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM
    Click to Show/Hide
External Link
TTD: D0F6HW
 Compound Name MesoTarg Investigative [152]
External Link
TTD: D0W5KO
 Compound Name PAT-PM-1 Investigative [152]
Synonyms
PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys
    Click to Show/Hide
External Link
TTD: D0U9YV
 Compound Name OP-04 Investigative [152]
Synonyms
OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon
    Click to Show/Hide
External Link
TTD: D0S0DY
 Compound Name VLI-27 Investigative [153]
Synonyms
AKT inhibitor (pancreatic cancer), NovaLead Pharma
    Click to Show/Hide
External Link
TTD: D0N7CY
 Compound Name GS-326 Investigative [152]
Synonyms
GS-326C
    Click to Show/Hide
External Link
CID: 3041004
TTD: D0LI3A
 Compound Name PX-12 Phase 2 [154]
External Link
CID: 219104
TTD: D0FT8G
DrugBank: DB05448
 Compound Name Prodigiosin Investigative [152]
External Link
CID: 135455579
TTD: D06YEE
 Compound Name Pbi-shPDX-1 LP Investigative [152]
External Link
TTD: D02FAI
 Compound Name Gastrin 17C diphtheria toxoid conjugate Investigative [152]
Synonyms
Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)
    Click to Show/Hide
External Link
TTD: D01PNR
 Compound Name HS-P1 Investigative [152]
Synonyms
HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics
    Click to Show/Hide
External Link
CID: 71537
TTD: D00JKJ
References
Ref 1 m(6)A-modified circRNA MYO1C participates in the tumor immune surveillance of pancreatic ductal adenocarcinoma through m(6)A/PD-L1 manner. Cell Death Dis. 2023 Feb 14;14(2):120. doi: 10.1038/s41419-023-05570-0.
Ref 2 Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-1157. doi: 10.1158/2326-6066.CIR-15-0059. Epub 2015 May 26.
Ref 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 4 PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
Ref 5 ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
Ref 6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 7 Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
Ref 8 National Cancer Institute Drug Dictionary (drug id 740856).
Ref 9 Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
Ref 10 GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015. doi: 10.21037/tlcr-20-608.
Ref 11 Clinical pipeline report, company report or official report of Klus Pharma
Ref 12 Clinical pipeline report, company report or official report of Alphamab Oncology.
Ref 13 PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun;34(5):409-18. doi: 10.1097/CJI.0b013e31821ca6ce.
Ref 14 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 16 National Cancer Institute Drug Dictionary (drug name INCB086550).
Ref 17 Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-Beta and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222. doi: 10.1016/j.jtho.2020.03.003. Epub 2020 Mar 13.
Ref 18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 19 Clinical pipeline report, company report or official report of BeiGene.
Ref 20 Clinical pipeline report, company report or official report of Gilead Sciences.
Ref 21 Clinical pipeline report, company report or official report of Numab Therapeutics.
Ref 22 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
Ref 23 ClinicalTrials.gov (NCT02937844) Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
Ref 24 Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Ref 25 CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules. 2019 Aug 1;24(15):2804. doi: 10.3390/molecules24152804.
Ref 26 ClinicalTrials.gov (NCT04050709) QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers. U.S. National Institutes of Health.
Ref 27 Clinical pipeline report, company report or official report of Kadmon.
Ref 28 ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
Ref 29 ClinicalTrials.gov (NCT04881045) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS. U.S.National Institutes of Health.
Ref 30 Clinical pipeline report, company report or official report of Merus.
Ref 31 Clinical pipeline report, company report or official report of Genmab.
Ref 32 Clinical pipeline report, company report or official report of Alpine Immune Sciences.
Ref 33 Clinical pipeline report, company report or official report of Shattuck Labs.
Ref 34 Clinical pipeline report, company report or official report of Inhibrx.
Ref 35 Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781. doi: 10.1158/1078-0432.CCR-20-3716. Epub 2021 Jan 13.
Ref 36 Clinical pipeline report, company report or official report of Innovent.
Ref 37 A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018). Expert Opin Ther Pat. 2018 Sep;28(9):665-678. doi: 10.1080/13543776.2018.1512706. Epub 2018 Sep 10.
Ref 38 Clinical pipeline report, company report or official report of Biocytogen
Ref 39 Clinical pipeline report, company report or official report of Biocytogen
Ref 40 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 41 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7316).
Ref 42 ClinicalTrials.gov (NCT02110147) Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria. U.S. National Institutes of Health.
Ref 43 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 44 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Ref 45 ClinicalTrials.gov (NCT01970371) A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE). U.S. National Institutes of Health.
Ref 46 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
Ref 47 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
Ref 48 ClinicalTrials.gov (NCT03816163) A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 49 ClinicalTrials.gov (NCT01741194) AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext. U.S. National Institutes of Health.
Ref 50 Clinical pipeline report, company report or official report of Advantagene.
Ref 51 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 52 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8087).
Ref 53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018609)
Ref 54 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004347)
Ref 55 ClinicalTrials.gov (NCT01579188) Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 56 Clinical pipeline report, company report or official report of Fibrogen.
Ref 57 ClinicalTrials.gov (NCT01523808) Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer. U.S. National Institutes of Health.
Ref 58 ClinicalTrials.gov (NCT01072981) Immunotherapy Study for Surgically Resected Pancreatic Cancer. U.S. National Institutes of Health.
Ref 59 ClinicalTrials.gov (NCT03504423) Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas. U.S. National Institutes of Health.
Ref 60 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 61 ClinicalTrials.gov (NCT01494506) Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 62 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5220).
Ref 63 ClinicalTrials.gov (NCT02923921) Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (Sequoia). U.S. National Institutes of Health.
Ref 64 ClinicalTrials.gov (NCT00337389) Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.. U.S. National Institutes of Health.
Ref 65 ClinicalTrials.gov (NCT01836432) Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. U.S. National Institutes of Health.
Ref 66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020300)
Ref 67 ClinicalTrials.gov (NCT03512756) A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 68 ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health.
Ref 69 ClinicalTrials.gov (NCT03801915) Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers. U.S. National Institutes of Health.
Ref 70 ClinicalTrials.gov (NCT02650804) A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients. U.S.National Institutes of Health.
Ref 71 ClinicalTrials.gov (NCT04698915) Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 72 Clinical pipeline report, company report or official report of Cytocom
Ref 73 ClinicalTrials.gov (NCT02912949) A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy). U.S.National Institutes of Health.
Ref 74 ClinicalTrials.gov (NCT01233375) Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 75 ClinicalTrials.gov (NCT01659502) Investigator's Initiated Phase II Study for Pancreatic Cancer Patients. U.S. National Institutes of Health.
Ref 76 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022260)
Ref 77 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 78 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031248)
Ref 79 Clinical pipeline report, company report or official report of GlobeImmune.
Ref 80 ClinicalTrials.gov (NCT01413087) Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 81 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004141)
Ref 82 ClinicalTrials.gov (NCT01186731) Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 83 ClinicalTrials.gov (NCT01608711) A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002. U.S. National Institutes of Health.
Ref 84 ClinicalTrials.gov (NCT01020006) Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine. U.S. National Institutes of Health.
Ref 85 Clinical pipeline report, company report or official report of Cornerstone pharmaceuticals.
Ref 86 ClinicalTrials.gov (NCT02640209) Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Ref 87 ClinicalTrials.gov (NCT01839487) PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer. U.S. National Institutes of Health.
Ref 88 ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health.
Ref 89 ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health.
Ref 90 ClinicalTrials.gov (NCT00203892) Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 91 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8453).
Ref 92 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7960).
Ref 93 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026972)
Ref 94 ClinicalTrials.gov (NCT04060342) GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 95 ClinicalTrials.gov (NCT04431258) A Phase I Open Label Followed by a Phase II Randomized, Controlled Study to Assess the Efficacy and Safety of ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic. U.S.National Institutes of Health.
Ref 96 ClinicalTrials.gov (NCT03854110) Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine. U.S. National Institutes of Health.
Ref 97 ClinicalTrials.gov (NCT02705196) Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer. U.S.National Institutes of Health.
Ref 98 ClinicalTrials.gov (NCT03681951) First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 99 VC-01's Path to the Clinic. Viacyte. 2015.
Ref 100 ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
Ref 101 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010209)
Ref 102 Clinical pipeline report, company report or official report of Northwest BioTherapeutics.
Ref 103 ClinicalTrials.gov (NCT02346370) A Phase 1b/2, Study of Pegylated Recombinant Human Hyaluronidase Combined With Docetaxel Versus Docetaxel Alone in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC.. U.S. National Institutes of Health.
Ref 104 ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
Ref 105 Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase ... Br J Cancer. 2007 Sep 3;97(5):598-604.
Ref 106 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 107 ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
Ref 108 ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Ref 109 ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
Ref 110 ClinicalTrials.gov (NCT02204085) A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 111 ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Ref 112 ClinicalTrials.gov (NCT04327986) Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer. U.S. National Institutes of Health.
Ref 113 ClinicalTrials.gov (NCT03819387) A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer. U.S. National Institutes of Health.
Ref 114 ClinicalTrials.gov (NCT04104672) A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies. U.S. National Institutes of Health.
Ref 115 Clinical pipeline report, company report or official report of Statera Biopharma
Ref 116 ClinicalTrials.gov (NCT03517176) CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 117 ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
Ref 118 ClinicalTrials.gov (NCT03323944) CAR T Cell Immunotherapy for Pancreatic Cancer
Ref 119 Clinical pipeline report, company report or official report of Otsuka Pharmaceutical Co Ltd.
Ref 120 ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
Ref 121 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 122 Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004 Dec;15(12):1825-33.
Ref 123 ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
Ref 124 ClinicalTrials.gov (NCT02159716) CART-meso in Mesothelin Expressing Cancers
Ref 125 ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
Ref 126 ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer
Ref 127 Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer. Int J Oncol. 2014 Mar;44(3):662-8.
Ref 128 ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Ref 129 ClinicalTrials.gov (NCT01761240) Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC. U.S. National Institutes of Health.
Ref 130 Clinical pipeline report, company report or official report of Quest PharmaTech.
Ref 131 ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
Ref 132 ClinicalTrials.gov (NCT01897415) Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer
Ref 133 ClinicalTrials.gov (NCT02706782) A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
Ref 134 2011 Pipeline of Seattle Genetics.
Ref 135 ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Ref 136 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038879)
Ref 137 ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Ref 138 ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
Ref 139 ClinicalTrials.gov (NCT03638193) Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
Ref 140 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017 Jul;27(7):753-761. doi: 10.1080/13543776.2017.1325465. Epub 2017 May 5.
Ref 141 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6468).
Ref 142 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010227)
Ref 143 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026002)
Ref 144 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 890).
Ref 145 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000894)
Ref 146 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2948).
Ref 147 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010558)
Ref 148 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035599)
Ref 149 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
Ref 150 2011 Pipeline of Anavex.
Ref 151 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017007)
Ref 152 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 153 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
Ref 154 A Randomized Phase II Study of PX-12, an Inhibitor of Thioredoxin in Patients With Advanced Cancer of the Pancreas Following Progression After a Gemcitabine-Containing Combination. Cancer Chemother Pharmacol. 2011 Mar;67(3):503-9.